Opthea (OPT) Stock Price, News & Analysis

Company Overview

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 504,572 shs
• Average Volume: N/A
• Market Capitalization: A$790.69 million
• P/E Ratio: N/A
• Dividend Yield: 0.24%
• Price Target: N/A
• Consensus Rating: N/A

OPT Stock Analysis - Frequently Asked Questions

How were Opthea's earnings last quarter?

Opthea Limited (ASX:OPT) released its earnings results on Friday, August, 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.00. Opthea had a positive trailing twelve-month return on equity of 543.34% and a negative net margin of 182,616.58%.

What other stocks do shareholders of Opthea own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include Skyworks Solutions (SWKS), Teladoc Health (TDOC), Vaxart (VXRT), Zion Oil & Gas (ZN), AST SpaceMobile (ASTS), Appian (APPN) and American Well (AMWL).

Company Calendar

• Last Earnings: 8/09/2019
• Today: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: ASX:OPT
• CIK: N/A
• Web: www.opthea.com
• Phone: 61 3 9826 0399
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$220.24 million
• Net Margins: -182,616.58%
• Pretax Margin: N/A
• Return on Equity: 543.34%
• Return on Assets: -83.43%

Debt

• Debt-to-Equity Ratio: -186.85
• Current Ratio: 2.94
• Quick Ratio: 4.25

Sales & Book Value

• Annual Sales: A$199.01 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 10.29
• Book Value: A($0.11) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,230,000,000
• Free Float: N/A
• Market Cap: A$790.69 million
• Optionable: Not Optionable
• Beta: 1.61